Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a ...

In a report released on April 4, Michael Cherny from Leerink Partners maintained a Hold rating on Medpace Holdings (MEDP – Research Report).

Shares of major health insurers jumped early Tuesday after the federal government announced a better-than-expected 2026 ...

In a report released on April 4, Michael Cherny from Leerink Partners maintained a Hold rating on Certara (CERT – Research Report), with a ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $3.65 […] ...

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges around ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. As of March 19, 2025, the average one-year ...